Meet The Professors - GIST 1

Select Publications

Blanke CD et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal
stromal tumors expressing KIT. J Clin Oncol 2008a;26(4):620-5. Abstract

Blanke CD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors
expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008b;26(4):626-32. Abstract

Blay JY et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation
of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007;25(9):1107-13. Abstract

Casali PG. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. Proc ASCO
2006;Abstract 9513.

Debiec-Rychter M; EORTC Soft Tissue and Bone Sarcoma Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer
2006;42(8):1093-103. Abstract

DeMatteo R et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The US Intergroup phase II trial ACOSOG Z9000. Presentation. Gastrointestinal Cancers Symposium
2008;Abstract 8.

DeMatteo R et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Proc ASCO 2007;Abstract 10079.

DeMatteo RP et al. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231(1):51-8. Abstract

Demetri GD et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368(9544):1329-38. Abstract

Demetri GD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-80. Abstract

George S et al. Sunitinib (SU) on a continuous daily dosing (CDD) schedule in pts with advanced GIST. Gastrointestinal Cancers Symposium 2008;Abstract 39.

George S et al. Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST. Proc ASCO 2007;Abstract 10015.

George S et al. Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST. Proc ASCO 2006;Abstract 9532.

Heinrich MC et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24(29):4764-74. Abstract

Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 2006;23(2):70-83. Abstract

Morgan JA et al. Sunitinib (SU) in a worldwide treatment-use trial of patients with GIST: Safety and efficacy. Gastrointestinal Cancers Symposium 2008;Abstract 31.